Garry A. Neil Elected to the FNIH Board of Directors
Garry A. Neil, MD was unanimously elected to the Foundation for the National Institutes of Health (FNIH) Board of Directors. He began his term May 16, 2012.
Garry A. Neil, MD, Corporate Vice President, Johnson & Johnson, and Vice-Chairman, PhRMA, Elected to the Foundation for the National Institutes of Health’s Board of Directors
BETHESDA, MD, July 9, 2012 — Garry A. Neil, MD was unanimously elected to the Foundation for the National Institutes of Health (FNIH) Board of Directors. He began his term May 16, 2012.
In addition to corporate vice president, Dr. Neil has held a number of senior positions within Johnson & Johnson, Astra Merck Inc., Astra Pharmaceuticals, Astra Zeneca, and Merck KGaA.
“Garry has broad experience in science, medicine, and pharmaceutical development,” according to Charles A. Sanders, MD, FNIH chairman. “He excels at maximizing existing strengths and leveraging collective resources for greater innovation.”
"Garry will make an excellent addition to the FNIH board," says FNIH board member and Chair of Friends of Cancer Research, Dr. Ellen Sigal. "Through his incredible leadership in science, medicine and pharmaceutical development and his deep understanding of the needs of patients, he has led Johnson and Johnson to countless important new discoveries. His unique skill set will be an invaluable addition to FNIH."
“Science continues to advance at a rapid pace, yet the complexity of scientific discovery today requires cooperation and collaboration between the public and private sectors to translate early technologies into the healthcare solutions of the future,” says Dr. Neil. “In my work with Johnson & Johnson, I have focused on developing broad networks to identify and help translate new science into breakthrough medicines, medical devices, diagnostics and consumer products. I am honored to serve on the FNIH board and look forward to applying my expertise to help further our mission.”
Dr. Neil is a fellow of the American College of Physicians and the American College of Gastroenterology, as well as a member of the American Association of Immunologists and the Society for Clinical Trials.
Among the board members’ responsibilities are helping guide the FNIH’s mission and purpose; ensuring effective organizational planning; ensuring adequate resources and managing them effectively; reviewing, monitoring, and strengthening FNIH’s programs and services; and enhancing FNIH’s public standing.
In total, eight people were elected to the FNIH Board of Directors this spring. They are: Mr. Jim Donovan; Paul Herrling, PhD; Ronald L. Krall, MD; Edison Liu, MD; Mr. Joel S. Marcus; Mr. Steven C. Mayer; and Mrs. Nina Solarz.
About the Foundation for the NIH
Established by the United States Congress to support the mission of the NIH — improving health through scientific discovery in the search for cure — the Foundation for the NIH is a leader in identifying and addressing complex scientific and health issues. The Foundation is a not-for-profit, 501(c)(3) charitable organization that raises private-sector funds for a broad portfolio of unique programs that complement and enhance the NIH priorities and activities. For additional information about the Foundation for the NIH, visit www.fnih.org.